British pharmaceutical giant AstraZeneca announced on Tuesday that it will delist its American Depositary Shares (ADS) and bonds from the Nasdaq exchange, with the transition of its ordinary shares and bonds to a direct listing on the New York Stock Exchange set to be completed after market close on January 30, 2026.

The company's ordinary shares and bond securities are expected to commence trading on the New York Stock Exchange on February 2, and will continue to use "AZN" as their ticker symbol.

This move is part of a plan, approved by AstraZeneca's shareholders, designed to unify the company's share listing structure. The initiative will enable investors to trade its ordinary shares across the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange.

Following the implementation of the unified structure, AstraZeneca will shift from trading ADSs—which represent its ordinary shares on a 2-to-1 ratio—to a direct listing of its $0.25 par value ordinary shares. This change is intended to streamline its multi-market trading arrangement.